Skip to main content
OpenTrials

Clinical trial condition

Adult Nasal Type Extranodal NK/T-cell Lymphoma

Explore clinical trials studying Adult Nasal Type Extranodal NK/T-cell Lymphoma. Study availability and eligibility vary by location and protocol.

51 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Adult Nasal Type Extranodal NK/T-cell Lymphoma trial results

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

NCT00336063

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Lymphoma, Lymphoma, Extranodal NK-T-Cell, +8 more
Locations
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Chinese University of Hong Kong-Prince of Wales Hospital Shatin, Hong Kong
  • National Cancer Center Hospital Tokyo, Japan
  • National University Hospital Singapore Singapore
View Trial Details
Completed

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +32 more
Locations
  • City of Hope Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • Northwestern University Chicago, Illinois, United States
  • Weill Cornell Medicine New York, United States
View Trial Details
Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

NCT03493451

Conditions
ALK-Positive Anaplastic Large Cell Lymphoma, ALK-negative Anaplastic Large Cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, +36 more
Locations
  • British Columbia Cancer Agency the Vancouver Centre Vancouver, British Columbia, Canada
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Beijing Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
View all 24 locations
View Trial Details
Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

NCT02168140

Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, +40 more
Locations
  • Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States
  • Abramson Cancer Center Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions